Long-term outcome of budesonide middle meatus treatment for chronic rhinosinusitis patients following endoscopic sinus surgery / 临床耳鼻咽喉头颈外科杂志
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
; (24): 203-208, 2016.
Article
in Zh
| WPRIM
| ID: wpr-749683
Responsible library:
WPRO
ABSTRACT
OBJECTIVE@#To investigate the long term clinical effect of budesonide treatment in middle meatus for chronic rhinosinusitis(CRS) following endoscopic sinus surgery (ESS).@*METHOD@#A total number of 53 patients with CRS received ESS were divided into two groups according to budesonide treatment budesonide-treated group with 21 cases (39.6%) and control group with 32 cases (60.4%). Gelatin sponges soaked with 1 ml budesonide suspension were put in middle meatus in budesonide-treated group, while only gelatin sponges were put in middle meatus in control group. Visual analogy score (VAS), sino-nasal outcome test-22 (SNOT-22) and Lund-Kennedy endoscopic scale were carried out before ESS and two years after ESS.@*RESULT@#In budesonide-treated group, there were a statistical difference before and after ESS in the VAS, SNOT-20 and Lund-Kennedy score (P<. 05). In control group, difference was also significant in VAS, SNOT-20 and Lund-Kennedy score before and after ESS (P < 0.05). The VAS gap of post-operative and pre-operative in two groups are significantly different (P<. 05). However, there was no significant difference in the SNOT-20 and Lund-Kennedy endoscopic scale gap before or after the operation between two groups.@*CONCLUSION@#It is safe, convenient and practicable to perform budesonide treatment in middle meatus following ESS, which can significantly ease the post-operative discomfort of nose.
Full text:
1
Index:
WPRIM
Main subject:
Paranasal Sinuses
/
Postoperative Period
/
Sinusitis
/
General Surgery
/
Rhinitis
/
Nose
/
Chronic Disease
/
Budesonide
/
Therapeutic Uses
/
Drug Therapy
Limits:
Humans
Language:
Zh
Journal:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
Year:
2016
Type:
Article